Orion Pharma (DHA:ORIONPHARM) EBITDA per Share: BDT1.85 (TTM As of Mar. 2026)


DHA:ORIONPHARM Orion Pharma Ltd DHA:ORIONPHARM
69 GF Score
Price BDT28.30
GF Value BDT20.28
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orion Pharma EBITDA per Share?

Orion Pharma DHA:ORIONPHARM -1.05% 69 EBITDA per Share is BDT1.85 as of Mar. 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 69/100 and a GF Value™ of BDT20.28 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 349 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 87.97% on this metric.

Orion Pharma's EBITDA per Share for the three months ended in Mar. 2026 was BDT0.60. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 was BDT1.85.

During the past 12 months, the average EBITDA per Share Growth Rate of Orion Pharma was -64.50% per year. During the past 3 years, the average EBITDA per Share Growth Rate was -26.70% per year. During the past 5 years, the average EBITDA per Share Growth Rate was -20.30% per year. During the past 10 years, the average EBITDA per Share Growth Rate was -7.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Orion Pharma's EBITDA per Share or its related term are showing as below:

DHA:ORIONPHARM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -26.7   Med: -10.7   Max: 14.6
Current: -26.7

During the past 12 years, the highest 3-Year average EBITDA per Share Growth Rate of Orion Pharma was 14.60% per year. The lowest was -26.70% per year. And the median was -10.70% per year.

DHA:ORIONPHARM's 3-Year EBITDA Growth Rate is ranked worse than
87.97% of 349 companies
in the Utilities - Independent Power Producers industry
Industry Median: 3 vs DHA:ORIONPHARM: -26.70

Orion Pharma's EBITDA for the three months ended in Mar. 2026 was BDT140 Mil.

During the past 12 months, the average EBITDA Growth Rate of Orion Pharma was -64.50% per year. During the past 3 years, the average EBITDA Growth Rate was -26.70% per year. During the past 5 years, the average EBITDA Growth Rate was -20.30% per year. During the past 10 years, the average EBITDA Growth Rate was -7.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 12 years, the highest 3-Year average EBITDA Growth Rate of Orion Pharma was 14.60% per year. The lowest was -26.70% per year. And the median was -10.70% per year.


Orion Pharma  (DHA:ORIONPHARM) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Orion Pharma EBITDA per Share Related Terms


Orion Pharma EBITDA per Share Historical Data

* Premium members only.

The historical data trend for Orion Pharma's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Pharma EBITDA per Share Chart

Orion Pharma Annual Data
Trend Dec14 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.38 7.38 6.76 6.44 2.91

Orion Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.96 -0.00 0.63 0.62 0.60
DHA:ORIONPHARM
69GF Score
Orion Pharma Ltd DHA:ORIONPHARM
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orion Pharma EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Orion Pharma's EBITDA per Share for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA per Share(A: Jun. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=680.03/234.000
=2.91

Orion Pharma's EBITDA per Share for the quarter that ended in Mar. 2026 is calculated as

EBITDA per Share(Q: Mar. 2026 )
=EBITDA/Shares Outstanding (Diluted Average)
=140.226/234.000
=0.60

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT1.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of BDT1.85 mean?
Orion Pharma (DHA:ORIONPHARM) has a EBITDA per Share of BDT1.85 as of Mar. 2026. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Orion Pharma and its competitors. According to the industry distribution chart, Orion Pharma ranks #307 out of 349 companies in the Utilities - Independent Power Producers industry, placing it in the top 88%.
Is Orion Pharma's EBITDA per Share too high?
Orion Pharma's current EBITDA per Share is BDT1.85. Based on the distribution chart, Orion Pharma ranks #307 out of 349 companies in the Utilities - Independent Power Producers industry, which is in the bottom quartile relative to peers. Overall, Orion Pharma has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's EBITDA per Share compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #307 out of 349 companies for EBITDA per Share. This places Orion Pharma in the lower half of its industry. The industry median EBITDA per Share is 3.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for an Utilities - Independent Power Producers company?
The median EBITDA per Share among Utilities - Independent Power Producers companies is 3.00, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median EBITDA per Share is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current EBITDA per Share is BDT1.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.28, compared to a current price of BDT28.30 — trading 39.5% above its estimated fair value. The current EBITDA per Share is BDT1.85. Orion Pharma's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current EBITDA per Share is BDT1.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued. The current stock price of BDT28.30 is trading 39.5% above its estimated GF Value™ of BDT20.28. GuruFocus considers Orion Pharma to be Significantly Overvalued.

Key valuation signals for DHA:ORIONPHARM:

  • EBITDA per Share: BDT1.85
  • GF Value™: BDT20.28 vs. price of BDT28.30 (39.5% above fair value)
  • GF Score™: 69/100 with 8 warning signs

No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orion Pharma Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
69GF Score

Get the complete analysis for DHA:ORIONPHARM

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT28.30
Price
BDT20.28
GF Value